封面文章：抗精神病药物诱导的体重增加由组胺H1受体介导的下丘脑AMP激酶激活所致。
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
作者信息
Kim Sangwon F, Huang Alex S, Snowman Adele M, Teuscher Cory, Snyder Solomon H
机构信息
The Solomon H. Snyder Department of Neuroscience, Departments of Pharmacology and Molecular Sciences and Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
出版信息
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9. doi: 10.1073/pnas.0611417104. Epub 2007 Feb 20.
Abstract
The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We report that orexigenic AAPDs potently and selectively activate hypothalamic AMP-kinase, an action abolished in mice with deletion of histamine H1 receptors. These findings may afford a means of developing more effective therapeutic agents and provide insight into the hypothalamic regulation of food intake.
摘要
非典型抗精神病药物（AAPDs）显著改善了精神分裂症的治疗，但某些AAPDs引起的显著体重增加阻碍了它们的使用。我们报告促食欲的AAPDs能有效且选择性地激活下丘脑AMP激酶，在组胺H1受体缺失的小鼠中该作用消失。这些发现可能为开发更有效的治疗药物提供一种方法，并深入了解下丘脑对食物摄入的调节。
相似文献
1
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.封面文章：抗精神病药物诱导的体重增加由组胺H1受体介导的下丘脑AMP激酶激活所致。
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9. doi: 10.1073/pnas.0611417104. Epub 2007 Feb 20.
2
Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.下丘脑组胺 H1 受体-AMPK 信号通路时间依赖性介导奥氮平诱导的雌性大鼠摄食过度和体重增加。
Psychoneuroendocrinology. 2014 Apr;42:153-64. doi: 10.1016/j.psyneuen.2014.01.018. Epub 2014 Jan 30.
3
The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?组氨 H1 和 H3 受体在摄食中的作用：非典型抗精神病药引起体重增加的机制？
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):1-4. doi: 10.1016/j.pnpbp.2009.11.009. Epub 2009 Nov 14.
4
The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.下丘脑 H1 受体拮抗作用在抗精神病药引起的体重增加中的作用。
CNS Drugs. 2013 Jun;27(6):423-34. doi: 10.1007/s40263-013-0062-1.
5
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.H1组胺受体亲和力可预测典型和非典型抗精神病药物的短期体重增加。
Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027.
6
Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.倍他司汀通过调节组胺能、神经肽Y和AMPK信号通路改善奥氮平引起的体重增加。
Psychoneuroendocrinology. 2014 Oct;48:77-86. doi: 10.1016/j.psyneuen.2014.06.010. Epub 2014 Jun 18.
7
H(1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.H(1)组胺受体亲和力可预测典型和非典型抗精神病药物的短期体重增加。
Neuropsychopharmacology. 2003 Dec;28(12):2209; author reply 2210-11. doi: 10.1038/sj.npp.1300291.
8
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.倍他司汀改善抗精神病药物所致体重增加：机制与临床意义
Pharmacol Res. 2016 Apr;106:51-63. doi: 10.1016/j.phrs.2016.02.011. Epub 2016 Feb 15.
9
Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways.利培酮诱导幼年雌性大鼠体重增加及运动活动减少：组胺能和神经肽Y通路的作用。
Pharmacol Res. 2015 May-Jun;95-96:20-6. doi: 10.1016/j.phrs.2015.03.004. Epub 2015 Mar 14.
10
Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.在雌性大鼠中，组胺H1受体激动剂可减弱奥氮平激活的迷走神经背核复合体中的AMPK信号传导。
Endocrinology. 2014 Dec;155(12):4895-904. doi: 10.1210/en.2014-1326. Epub 2014 Sep 29.
引用本文的文献
1
Antipsychotic medications and risk of respiratory failure in the respiratory high dependency unit.抗精神病药物与呼吸高依赖病房呼吸衰竭风险
BJPsych Open. 2024 Dec 4;10(6):e211. doi: 10.1192/bjo.2024.773.
2
Histamine H-receptor-mediated modulation of NMDA receptors signaling responses.组氨酸 H 受体介导的 NMDA 受体信号转导反应调节。
Pharmacol Res Perspect. 2024 Oct;12(5):e1216. doi: 10.1002/prp2.1216.
3
Olanzapine Induces Adipogenesis and Glucose Uptake by Activating Glycolysis and Synergizing with the PI3K-AKT Pathway.奥氮平通过激活糖酵解并与PI3K-AKT信号通路协同作用来诱导脂肪生成和葡萄糖摄取。
Curr Neuropharmacol. 2025;23(4):412-425. doi: 10.2174/1570159X22666240815120547.
4
Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia.氯氮平单一疗法对精神分裂症患者肠道微生物群和代谢的影响。
Front Microbiol. 2023 Sep 6;14:1253156. doi: 10.3389/fmicb.2023.1253156. eCollection 2023.
5
Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment.反映低多巴胺能信号传导的多位点基因谱与抗精神病药物治疗所致肥胖和心脏代谢紊乱直接相关。
Pharmaceutics. 2023 Aug 14;15(8):2134. doi: 10.3390/pharmaceutics15082134.
6
Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia.重复经颅磁刺激联合奥氮平和阿立哌唑治疗难治性精神分裂症
World J Psychiatry. 2023 Jul 19;13(7):453-460. doi: 10.5498/wjp.v13.i7.453.
7
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.精神分裂症新兴治疗方法的代谢潜力、疗效和安全性增加。
CNS Drugs. 2023 Jul;37(7):545-570. doi: 10.1007/s40263-023-01022-7. Epub 2023 Jul 20.
8
Histaminergic regulation of food intake.组胺能调节摄食。
Front Endocrinol (Lausanne). 2023 Jun 27;14:1202089. doi: 10.3389/fendo.2023.1202089. eCollection 2023.
9
Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine.增强型 L-β-氨基异丁酸与氯氮平治疗抵抗性精神分裂症的发病机制及不良反应有关。
Biomolecules. 2023 May 19;13(5):862. doi: 10.3390/biom13050862.
10
Candidate biomarkers in psychiatric disorders: state of the field.精神疾病中的候选生物标志物：该领域的现状。
World Psychiatry. 2023 Jun;22(2):236-262. doi: 10.1002/wps.21078.
本文引用的文献
1
AMP-activated protein kinase as a drug target.AMP激活的蛋白激酶作为一种药物靶点。
Annu Rev Pharmacol Toxicol. 2007;47:185-210. doi: 10.1146/annurev.pharmtox.47.120505.105304.
2
Differential metabolic effects of antipsychotic treatments.抗精神病药物治疗的差异代谢效应。
Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S149-55. doi: 10.1016/j.euroneuro.2006.06.003. Epub 2006 Jul 25.
3
Control of energy homeostasis: role of enzymes and intermediates of fatty acid metabolism in the central nervous system.能量稳态的调控：脂肪酸代谢的酶和中间产物在中枢神经系统中的作用
Annu Rev Nutr. 2006;26:23-44. doi: 10.1146/annurev.nutr.25.050304.092532.
4
Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain.培养能量感知的头脑：AMP 激活的蛋白激酶作为大脑中的多功能代谢传感器。
J Physiol. 2006 Jul 1;574(Pt 1):85-93. doi: 10.1113/jphysiol.2006.110122. Epub 2006 May 11.
5
AMP-activated protein kinase--development of the energy sensor concept.AMP激活的蛋白激酶——能量传感器概念的发展
J Physiol. 2006 Jul 1;574(Pt 1):7-15. doi: 10.1113/jphysiol.2006.108944. Epub 2006 Apr 27.
6
D-aspartate regulates melanocortin formation and function: behavioral alterations in D-aspartate oxidase-deficient mice.D-天冬氨酸调节黑皮质素的形成和功能：D-天冬氨酸氧化酶缺陷小鼠的行为改变。
J Neurosci. 2006 Mar 8;26(10):2814-9. doi: 10.1523/JNEUROSCI.5060-05.2006.
7
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.奥氮平和氯氮平在啮齿动物中与体重相关的激素和代谢效应。
Obesity (Silver Spring). 2006 Jan;14(1):36-51. doi: 10.1038/oby.2006.6.
8
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.抗精神病药物对慢性精神分裂症患者的疗效。
N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.
9
Olanzapine and weight gain.奥氮平与体重增加。
Am J Psychiatry. 2005 Sep;162(9):1764-5; author reply 1765. doi: 10.1176/appi.ajp.162.9.1764.
10
AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.AMP激活的蛋白激酶：古老的能量计量器为现代新陈代谢理解提供线索
Cell Metab. 2005 Jan;1(1):15-25. doi: 10.1016/j.cmet.2004.12.003.
Zotero 插件